ArticleScientific reports2026
Cubosomal nanoparticles of lycopene as a novel platform for enhancement in antioxidant and anticancer properties with a molecular docking study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of ursolic acid-loaded cubosomal nanocarriers: enhanced dissolution, pharmacokinetics, bioavailability, and anticancer activity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lycopene is the highest concentration of red, hydrophobic carotenoids in various fruits and vegetables. Because of low solubility and poor bioavailability, a delivery system must be utilized to have a prolonged target therapeutic site. The current research is focused on assessing the potential antioxidant and anticancer activity of Lycopene Cubosomal Nanoparticles against the HT-29 colon cancer cell line. The nanoformulation was ensured by various characterization methods, including FTIR, TEM, SEM, particle size, and zeta potential. The structure of Lycopene was energy-minimized and was docked into the ATP-binding pocket using SwissDock with AutoDock Vina as backend. DPPH and ABTS were used for the presentation of antioxidant activities. In addition, anticancer activity of the compounds was tested by MTT viability test. Cell cycle and annexin-V/PI double staining were also investigated by flow cytometry. Further, gene expression and protein content of different markers PI3K, AKT, mTOR, Caspase-3, and Bcl-2 were analyzed by qRT-PCR and ELISA methods. The results presented that Lycopene Cubosomal Nanoparticles are more active than Lycopene as regards antioxidant and anticancer activity. Additionally, PI3K, AKT, mTOR, and Bcl-2 gene expression and content were decreased, and the gene expression and content of Caspase-3 were increased in both treatments, particularly pointing towards Lycopene Cubosomal Nanoparticles. Highly soluble Lycopene Cubosomal Nanoparticles were revealed to be more active than weakly soluble Lycopene alone, in that activity was enhanced over weakly soluble Lycopene alone, and Lycopene Cubosomal Nanoparticles were found to be more active than Lycopene alone as an antioxidant and anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.